Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain

Human Molecular Genetics

Volumn 23, Issue 15, 2014, Pages 4051-4063

  Lim, Nastasia K H ^a   Hung, Lin W ^a,b   Pang, Terence Y ^a   Mclean, Catriona A ^c   Liddell, Jeffrey R ^a   Hilton, James B ^a   Li, Qiao Xin ^a   White, Anthony R ^a   Hannan, Anthony J ^a   Crouch, Peter J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA CATENIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; GLYCOGEN SYNTHASE KINASE 3; HUNTINGTIN; MUTANT PROTEIN; PARAQUAT; COLLAPSIN RESPONSE MEDIATOR PROTEIN-2; CTNNB1 PROTEIN, HUMAN; HTT PROTEIN, HUMAN; NERVE PROTEIN; SIGNAL PEPTIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN; BRAIN LEVEL; BRAIN TISSUE; CEREBELLUM; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MIDDLE AGED; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VERY ELDERLY; ANIMAL; BIOSYNTHESIS; BRAIN CORTEX; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

ADENOSINE TRIPHOSPHATE; AGED; AGED, 80 AND OVER; ANIMALS; BETA CATENIN; CELL LINE; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HUNTINGTON DISEASE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; PARAQUAT; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84903985237     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu119     Document Type: Article

References (55)

1. Ha, A.D. and Fung, V.S. (2012) Huntington's disease. Curr. Opin. Neurol., 25, 491-498.
2. Langbehn, D.R., Brinkman, R.R., Falush, D., Paulsen, J.S. and Hayden, M.R. (2004) A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet., 65, 267-277.
3. Embi, N., Rylatt, D.B. and Cohen, P. (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem., 107, 519-527.
4. Soutar, M.P., Kim, W.Y., Williamson, R., Peggie, M., Hastie, C.J., McLauchlan, H., Snider, W.D., Gordon-Weeks, P.R. and Sutherland, C. (2010) Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J. Neurochem., 115, 974-983.
5. Ali, A., Hoeflich, K.P. and Woodgett, J.R. (2001) Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev., 101, 2527-2540.
6. Medina, M. and Wandosell, F. (2011) Deconstructing GSK-3: The fine regulation of its activity. Int. J. Alzheimers Dis., 2011, 479249.
7. Sutherland, C. (2011) What are the bona fide GSK3 substrates? Int. J. Alzheimers Dis., 2011, 505607.
8. Smillie, K.J. and Cousin, M.A. (2011) The role of GSK3 in presynaptic function. Int. J. Alzheimers Dis., 2011, 263673.
9. Henriksen, E.J. (2010) Dysregulation of glycogen synthase kinase-3 in skeletal muscle and the etiology of insulin resistance and type 2 diabetes. Curr. Diabetes Rev., 6, 285-293.
10. Luo, J. (2009) Glycogen synthase kinase 3β (GSK3b) in tumorigenesis and cancer chemotherapy. Cancer Lett., 273, 194-200.
11. Hanger, D.P., Hughes, K., Woodgett, J.R., Brion, J.P. and Anderton, B.H. (1992) Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett., 147, 58-62.
12. Mines, M.A., Beurel, E. and Jope, R.S. (2011) Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3. Int. J. Alzheimers Dis., 2011, 861072.
13. Beaulieu, J.M. (2012) A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J. Psychiatry Neurosci., 37, 7-16.
14. Ju, T.C., Lin, Y.S. and Chern, Y. (2012) Energy dysfunction in Huntington's disease: insights from PGC-1alpha, AMPK, andCKB.Cell Mol. Life Sci., 69, 4107-4120.
15. Gines, S., Ivanova, E., Seong, I.S., Saura, C.A. and MacDonald, M.E. (2003) Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J. Biol. Chem., 278, 50514-50522.
16. Chiu, C.T., Liu, G., Leeds, P. and Chuang, D.M. (2011) Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology, 36, 2406-2421.
17. Sarkar, S., Krishna, G., Imarisio, S., Saiki, S., O'Kane, C.J. and Rubinsztein, D.C. (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum. Mol. Genet., 17, 170-178.
18. Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V.C., Sharp, A.H., Persichetti, F., Cattaneo, E. and MacDonald, M.E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet., 9, 2799-2809.
19. Milakovic, T., Quintanilla, R.A. and Johnson, G.V. (2006) Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J. Biol. Chem., 281, 34785-34795.
20. Orr, A.L., Li, S., Wang, C.E., Li, H., Wang, J., Rong, J., Xu, X., Mastroberardino, P.G., Greenamyre, J.T. and Li, X.J. (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci., 28, 2783-2792.
21. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
22. Song, W., Chen, J., Petrilli, A., Liot, G., Klinglmayr, E., Zhou, Y., Poquiz, P., Tjong, J., Pouladi, M.A., Hayden, M.R. et al. (2011) Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med., 17, 377-382.
23. Wang, H., Lim, P.J., Karbowski, M. and Monteiro, M.J. (2009) Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet., 18, 737-752.
24. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
25. Delaney, S.M. and Geiger, J.D. (1996) Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation. J. Neurosci. Methods, 64, 151-156.
26. Mochel, F., Durant, B., Meng, X., O'Callaghan, J., Yu, H., Brouillet, E., Wheeler, V.C., Humbert, S., Schiffmann, R. and Durr, A. (2012) Early alterations of brain cellular energy homeostasis in Huntington disease models. J. Biol. Chem., 287, 1361-1370.
27. Paulsen, J.S. (2009) Functional imaging in Huntington's disease. Exp. Neurol., 216, 272-277.
28. Hayden, M.R., Martin, W.R., Stoessl, A.J., Clark, C., Hollenberg, S., Adam, M.J., Ammann, W., Harrop, R., Rogers, J., Ruth, T. et al. (1986) Positron emission tomography in the early diagnosis of Huntington's disease. Neurology, 36, 888-894.
29. Mazziotta, J.C., Phelps, M.E., Pahl, J.J., Huang, S.C., Baxter, L.R., Riege, W.H., Hoffman, J.M., Kuhl, D.E., Lanto, A.B., Wapenski, J.A. et al. (1987) Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N. Engl. J. Med., 316, 357-362.
30. Ciarmiello, A., Giovacchini, G., Orobello, S., Bruselli, L., Elifani, F. and Squitieri, F. (2012) 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur. J. Nucl. Med. Mol. Imaging, 39, 1030-1036.
31. Shin, H., Kim, M.H., Lee, S.J., Lee, K.H., Kim, M.J., Kim, J.S. and Cho, J.W. (2013) Decreased metabolism in the cerebral cortex in early-stage Huntington's disease: A possible biomarker of disease progression? J. Clin. Neurol., 9, 21-25.
32. Kuwert, T., Lange, H.W., Langen, K.J., Herzog, H., Aulich, A. and Feinendegen, L.E. (1990) Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain, 113, 1405-1423.
33. Costa, V. and Scorrano, L. (2012) Shaping the role of mitochondria in the pathogenesis of Huntington's disease. EMBO J., 31, 1853-1864.
34. Reddy, P.H. and Shirendeb, U.P. (2012) Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim. Biophys. Acta, 1822, 101-110.
35. Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J. and Lesort, M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet., 13, 1407-1420.
36. Damiano, M., Diguet, E., Malgorn, C., D'Aurelio, M., Galvan, L., Petit, F., Benhaim, L., Guillermier, M., Houitte, D., Dufour, N. et al. (2013) A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Hum. Mol. Genet., 22, 3869-3882.
37. Shirendeb, U.P., Calkins, M.J., Manczak, M., Anekonda, V., Dufour, B., McBride, J.L., Mao, P. and Reddy, P.H. (2012) Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum. Mol. Genet., 21, 406-420.
38. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1a by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
39. Chiang, M.C., Chen, C.M., Lee, M.R., Chen, H.W., Chen, H.M., Wu, Y.S., Hung, C.H., Kang, J.J., Chang, C.P., Chang, C. et al. (2010) Modulation of energy deficiency inHuntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum. Mol. Genet., 19, 4043-4058.
40. Carmichael, J., Sugars, K.L., Bao, Y.P. and Rubinsztein, D.C. (2002) Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem., 277, 33791-33798.
41. Valencia, A., Reeves, P.B., Sapp, E., Li, X., Alexander, J., Kegel, K.B., Chase, K., Aronin, N. and DiFiglia, M. (2010) Mutant huntingtin and glycogen synthase kinase 3-β accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J. Neurosci. Res., 88, 179-190.
42. van Eyk, C.L., O'Keefe, L.V., Lawlor, K.T., Samaraweera, S.E., McLeod, C.J., Price, G.R., Venter, D.J. and Richards, R.I. (2011) Perturbation of the Akt/Gsk3-β signalling pathway is common to Drosophila expressing expanded untranslated CAG, CUG and AUUCU repeat RNAs. Hum. Mol. Genet., 20, 2783-2794.
43. D'Hooge, R. and DeDeyn, P.P. (2001) Applications of theMorriswatermaze in the study of learning and memory. Brain Res. Brain Res. Rev., 36, 60-90.
44. Godin, J.D., Poizat, G., Hickey, M.A., Maschat, F. and Humbert, S. (2010) Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J., 29, 2433-2445.
45. Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S. and Kikuchi, A. (1998) Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin. EMBO J., 17, 1371-1384.
46. Maguschak, K.A. and Ressler, K.J. (2012) The dynamic role of β-catenin in synaptic plasticity. Neuropharmacology, 62, 78-88.
47. Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, S., Kikuchi, A. and Kaibuchi, K. (2005) GSK-3β regulates phosphorylation of CRMP-2 and neuronal polarity. Cell, 120, 137-149.
48. Arimura, N., Menager, C., Fukata, Y. and Kaibuchi, K. (2004) Role of CRMP-2 in neuronal polarity. J. Neurobiol., 58, 34-47.
49. Yamashita, N. and Goshima, Y. (2012) Collapsin response mediator proteins regulate neuronal development and plasticity by switching their phosphorylation status. Mol. Neurobiol., 45, 234-246.
50. Charrier, E., Reibel, S., Rogemond, V., Aguera, M., Thomasset, N. and Honnorat, J. (2003) Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol. Neurobiol., 28, 51-64.
51. Soutar, M.P., Thornhill, P., Cole, A.R. and Sutherland, C. (2009) Increased CRMP2 phosphorylation is observed in Alzheimer's disease; does this tell us anything about disease development? Curr. Alzheimer Res., 6, 269-278.
52. Crews, L., Ruf, R., Patrick, C., Dumaop, W., Trejo-Morales, M., Achim, C.L., Rockenstein, E. and Masliah, E. (2011) Phosphorylation of collapsin response mediator protein-2 disrupts neuronal maturation in a model of adult neurogenesis: Implications for neurodegenerative disorders. Mol. Neurodegener., 6, 67.
53. Brittain, J.M., Piekarz, A.D., Wang, Y., Kondo, T., Cummins, T.R. and Khanna, R. (2009) An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J. Biol. Chem., 284, 31375-31390.
54. Brittain, J.M., Wang, Y., Eruvwetere, O. and Khanna, R. (2012) Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS Lett., 586, 3813-3818.
55. II(atsm) in the SOD1G37R mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Fontotemporal Degener., 14, 586-590.